PURPOSE: Acyclic nucleoside phosphonates possess unique antiviral and antineoplastic activities; however, their polar phosphonate moiety is associated with low ability to cross biological membranes. We explored the potential of transdermal and topical delivery of 2,6-diaminopurine derivative cPr-PMEDAP. METHODS: In vitro diffusion of cPr-PMEDAP was investigated using formulations at different pH and concentration and with permeation enhancer through porcine and human skin. RESULTS: Ability of 0.1-5% cPr-PMEDAP to cross human skin barrier was very low with flux values ~40 ng/cm(2)/h, the majority of compound found in the stratum corneum. The highest permeation rates were found at pH 6; increased donor concentration had no influence. The permeation enhancer dodecyl 6-dimethylaminohexanoate (DDAK, 1%) increased flux of cPr-PMEDAP (up to 61 times) and its concentration in nucleated epidermis (up to ~0.5 mg of cPr-PMEDAP/g of the tissue). No deamination of cPr-PMEDAP into PMEG occurred during permeation studies, but N-dealkylation into PMEDAP mediated by skin microflora was observed. CONCLUSIONS: Transdermal or topical application of cPr-PMEDAP enabled by the permeation enhancer DDAK may provide an attractive alternative route of administration of this potent antitumor and antiviral compound.
PURPOSE: Acyclic nucleoside phosphonates possess unique antiviral and antineoplastic activities; however, their polar phosphonate moiety is associated with low ability to cross biological membranes. We explored the potential of transdermal and topical delivery of 2,6-diaminopurine derivative cPr-PMEDAP. METHODS: In vitro diffusion of cPr-PMEDAP was investigated using formulations at different pH and concentration and with permeation enhancer through porcine and human skin. RESULTS: Ability of 0.1-5% cPr-PMEDAP to cross human skin barrier was very low with flux values ~40 ng/cm(2)/h, the majority of compound found in the stratum corneum. The highest permeation rates were found at pH 6; increased donor concentration had no influence. The permeation enhancer dodecyl 6-dimethylaminohexanoate (DDAK, 1%) increased flux of cPr-PMEDAP (up to 61 times) and its concentration in nucleated epidermis (up to ~0.5 mg of cPr-PMEDAP/g of the tissue). No deamination of cPr-PMEDAP into PMEG occurred during permeation studies, but N-dealkylation into PMEDAP mediated by skin microflora was observed. CONCLUSIONS: Transdermal or topical application of cPr-PMEDAP enabled by the permeation enhancer DDAK may provide an attractive alternative route of administration of this potent antitumor and antiviral compound.
Authors: B Otová; K Francová; F Franĕk; P Koutník; I Votruba; A Holy; M Sladká; J Schramlová Journal: Anticancer Res Date: 1999 Jul-Aug Impact factor: 2.480
Authors: Katerina Vávrová; Katerina Lorencová; Jana Klimentová; Jakub Novotný; Alexandr Hrabálek Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2007-03-18 Impact factor: 3.205
Authors: Hans Reiser; Jianying Wang; Lee Chong; William J Watkins; Adrian S Ray; Riri Shibata; Gabriel Birkus; Tomas Cihlar; Sylvia Wu; Bei Li; Xiaohong Liu; Ilana N Henne; Grushenka H I Wolfgang; Manoj Desai; Gerald R Rhodes; Arnold Fridland; William A Lee; William Plunkett; David Vail; Douglas H Thamm; Robert Jeraj; Daniel B Tumas Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531
Authors: Grushenka H I Wolfgang; Riri Shibata; Jianying Wang; Adrian S Ray; Sylvia Wu; Edward Doerrfler; Hans Reiser; William A Lee; Gabriel Birkus; Neil D Christensen; Graciela Andrei; Robert Snoeck Journal: Antimicrob Agents Chemother Date: 2009-04-27 Impact factor: 5.191
Authors: Jakub Novotný; Petra Kovaríková; Michal Novotný; Barbora Janůsová; Alexandr Hrabálek; Katerina Vávrová Journal: Pharm Res Date: 2008-11-14 Impact factor: 4.200